Ultragenyx announced the completion of enrollment in Global Phase 1/2 Trial of GTX-102 in pediatric patients living with Angelman syndrome and data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024.
Read press release here.
